Laplace Interventional Achieves Milestone with First Patients in TRIUMPH Trial for New Heart Valve System

Laplace Interventional Reaches Key Milestone in TRIUMPH Trial

In a significant development in the field of cardiac care, Laplace Interventional™, a Minnesota-based company, has officially enrolled and treated the first three patients within the randomized cohort of its pioneering TRIUMPH pivotal trial. This exciting advancement occurred at two prominent medical facilities: Ballad Health in Kingsport, Tennessee, and Oklahoma Heart Institute in Tulsa, Oklahoma. The structural heart teams, led by Dr. Gaurav Rana and Dr. Kamran Muhammad respectively, successfully performed the procedures, marking a critical step in the trial's progression.

The TRIUMPH trial is designed to evaluate the effectiveness of Laplace Interventional's innovative prosthetic valve intended for treating patients suffering from Tricuspid Regurgitation (TR). Delivered through a minimally invasive procedure, the valve can be accessed via a vein in either the neck or groin, making it a less complicated option compared to traditional surgery. The trial aims to compare outcomes for patients receiving this novel treatment against those receiving standard Transcatheter Tricuspid Valve Replacement (TTVR) received commercially.

At the helm of the TRIUMPH trial are three distinguished global principal investigators: Dr. Charanjit Rihal from Mayo Clinic in Rochester, MN; Dr. Kashish Goel from Vanderbilt University Medical Center in Nashville, TN; and Dr. Brandon Jones from Providence St. Vincent Medical Center in Portland, OR. Under their expertise, the trial is expected to contribute significantly to the medical community’s understanding of TR treatment options.

Ramji Iyer, PhD, the Founder and CEO of Laplace Interventional, expressed heartfelt congratulations to the teams involved in the first patient treatments. Iyer stated, “On behalf of the Laplace team, I would like to congratulate Dr. Rana and his team at Ballad Health as well as Dr. Muhammad and his team at Oklahoma Heart Institute for treating the first patients in this pivotal study. This milestone is of immense significance to our company and sets the much-needed early clinical momentum for the pivotal trial.”

In a related note, Laplace also announced that the preliminary outcomes from its Trans-jugular (TJ) Early Feasibility Study (EFS) will be presented by Dr. Kashish Goel during the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference on November 2, 2026, at 2:15 PM Pacific Time.

Laplace Interventional™, Inc. is a privately held clinical-stage medical device enterprise based out of Minnesota. The company’s focus is on developing an effective TTVR solution for the over 1.6 million individuals in the United States suffering from TR. Notably, the device currently is restricted for investigational use and is not available commercially in the U.S. or any other countries, which underlines the critical nature of ongoing clinical trials to ensure its safety and efficacy.

In summary, the successful enrollment and treatment of the first three patients in the TRIUMPH pivotal trial signify a major milestone for Laplace Interventional and its innovative cardiac technologies. As researchers anticipate more data and outcomes, this could potentially reshape the treatment landscape for Tricuspid Regurgitation, offering hope to countless patients in need.